Results of a study investigating brentuximab vedotin combined with gemcitabine for treatment of relapsed PTCL.
Home / Resource Library / Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study